Bedrijfsoverzicht
Immunocore Holdings plc is primarily engaged in the development and commercialization of immunomodulating medicines designed for patients suffering from cancer, infectious diseases, and autoimmune conditions across the United States, Europe, and international markets. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, a space characterized by high research and development costs and the commercialization of novel therapeutic agents. Immunocore Holdings plc currently possesses a market capitalization of $1.57 billion, generates $400.02 million in annual revenue, and employs a workforce of 524 individuals. These valuation and operational metrics indicate that the company has established itself as a mid-cap entity with significant revenue generation capabilities relative to its peer group, suggesting a substantial operational footprint in the global biotechnology landscape.
Financiële gezondheid
The company reported a revenue of $400.02 million over the trailing twelve months, yet recorded a net income of $-35,514,000 and an EBITDA of $-22,359,000, revealing a significant gap between top-line sales and profitability that highlights a heavy cost structure typical of early-stage commercialization phases. Despite the negative net income and EBITDA, Immunocore Holdings plc maintains a free cash flow of $23.96 million, which indicates a degree of financial flexibility allowing the company to fund operations without immediate reliance on external equity financing. The gross margin stands at an impressive 96.5%, reflecting high margins on product sales, whereas the operating margin is 0.0% and the profit margin is -8.9%, signaling that while sales are efficient, overhead costs are currently consuming the entire operating profit and further eroding net earnings. On the liability side, the company holds $864.15 million in cash against $436.69 million in debt, resulting in a debt-to-equity ratio of 114.61%, which suggests a leveraged balance sheet where liabilities exceed equity, yet the substantial cash reserve provides a buffer against this leverage. Liquidity is robust with a current ratio of 4.04, indicating that the company holds more than four times the current assets necessary to cover its short-term obligations, thereby mitigating liquidity risk. Finally, the return on equity is -9.6% and the return on assets is -1.5%, metrics that reveal that management is currently deploying capital in ways that generate negative returns, a common characteristic for biotechnology firms investing heavily in growth initiatives before achieving sustained profitability.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not applicable (N/A) due to negative earnings, while the forward P/E is -22.02, implying that the market expects earnings to turn positive or that valuation is currently based on non-earnings multiples given the negative earnings trajectory. The price-to-book ratio is 4.13, indicating that the market values the company at over four times its book value, which often reflects the intangible assets, intellectual property, and pipeline potential that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 3.94 and the EV/EBITDA of -51.28 suggest that the company is priced based on revenue generation rather than current profitability, a standard approach for biotechnology firms where future cash flows from drug approvals are expected to drive value. The stock has traded between a 52-week low of $26.37 and a 52-week high of $40.72, placing the current valuation context within a range where the company has experienced significant volatility but remains below its recent peak. The beta of 0.83 indicates that the stock's price volatility is lower than the broader market, suggesting that Immunocore Holdings plc is less sensitive to general market fluctuations compared to high-beta biotechnology peers.
Growth & Income
Revenue growth year-over-year stands at 24.3%, demonstrating a strong expansion in sales, whereas earnings growth is not applicable (N/A) due to negative net income, implying that top-line expansion is outpacing the realization of profits as the company navigates its commercialization strategy. As a non-dividend payer, Immunocore Holdings plc does not distribute a dividend yield or pays a payout ratio of 0.0%, meaning the company retains all earnings and reinvests capital into research, development, and commercialization efforts rather than providing income to shareholders. This strategy prioritizes long-term asset growth and pipeline advancement over immediate shareholder returns, which is typical for biotechnology companies in the development phase. The overall growth and income profile is characterized by robust revenue expansion and a zero-dividend policy that channels resources back into the business to support future profitability milestones.